Literature DB >> 28685959

Targeting cholesterol transport in circulating melanoma cells to inhibit metastasis.

Yu-Chi Chen1, Raghavendra Gowda1, Raymond K Newswanger2, Patrick Leibich2, Barry Fell3, Gerson Rosenberg2, Gavin P Robertson1,4,5,6,7,8.   

Abstract

Despite recent breakthroughs in targeted- and immune-based therapies, rapid development of drug resistance remains a hurdle for the long-term treatment of patients with melanoma. Targeting metastatically spreading circulating tumor cells (CTCs) may provide an additional approach to manage melanoma. This study investigates whether targeting cholesterol transport in melanoma CTCs can retard metastasis development. Nanolipolee-007, the liposomal form of leelamine, reduced melanoma metastasis in both a novel in vitro flow system mimicking the circulating system and in experimental as well as spontaneous animal metastasis models, irrespective of the BRAF mutational status of the CTCs. Leelamine led to cholesterol trapping in lysosomes, which subsequently shut down receptor-mediated endocytosis, endosome trafficking, and inhibited the major oncogenic signaling cascades important for survival such as the AKT pathway. As pAKT is important in CTC survival, inhibition by targeting cholesterol metabolism led to apoptosis, suggesting this approach might be particularly effective for those CTCs having high levels of pAKT to aid survival in the circulation system.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  cholesterol; circulating tumor cells; melanoma; metastasis; pAKT

Mesh:

Substances:

Year:  2017        PMID: 28685959     DOI: 10.1111/pcmr.12614

Source DB:  PubMed          Journal:  Pigment Cell Melanoma Res        ISSN: 1755-1471            Impact factor:   4.693


  10 in total

1.  Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer.

Authors:  Kai-Li Zhang; Wen-Wei Zhu; Sheng-Hao Wang; Chao Gao; Jun-Jie Pan; Zun-Guo Du; Lu Lu; Hu-Liang Jia; Qiong-Zhu Dong; Jin-Hong Chen; Ming Lu; Lun-Xiu Qin
Journal:  Theranostics       Date:  2021-04-27       Impact factor: 11.556

2.  Activating Sphingosine-1-phospahte signaling in endothelial cells increases myosin light chain phosphorylation to decrease endothelial permeability thereby inhibiting cancer metastasis.

Authors:  Yu-Chi Chen; Saketh S Dinavahi; Qilong Feng; Raghavendra Gowda; Srinivasa Ramisetti; Xinghai Xia; Kyle B LaPenna; Venkat R Chirasani; Sung Hyun Cho; Susan L Hafenstein; Madhu Babu Battu; Arthur Berg; Arun K Sharma; Tom Kirchhausen; Nikolay V Dokholyan; Shantu Amin; Pingnian He; Gavin P Robertson
Journal:  Cancer Lett       Date:  2021-02-16       Impact factor: 9.756

3.  Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism.

Authors:  Young-Seon Kim; Yoon-Mi Lee; Taek-In Oh; Dong Hoon Shin; Geon-Hee Kim; Sang-Yeon Kan; Hyeji Kang; Ji Hyung Kim; Byeong Mo Kim; Woo Jong Yim; Ji-Hong Lim
Journal:  Int J Mol Sci       Date:  2018-10-12       Impact factor: 5.923

4.  Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data.

Authors:  Lazaro Hiram Betancourt; Krzysztof Pawłowski; Jonatan Eriksson; A Marcell Szasz; Shamik Mitra; Indira Pla; Charlotte Welinder; Henrik Ekedahl; Per Broberg; Roger Appelqvist; Maria Yakovleva; Yutaka Sugihara; Kenichi Miharada; Christian Ingvar; Lotta Lundgren; Bo Baldetorp; Håkan Olsson; Melinda Rezeli; Elisabet Wieslander; Peter Horvatovich; Johan Malm; Göran Jönsson; György Marko-Varga
Journal:  Sci Rep       Date:  2019-03-26       Impact factor: 4.379

5.  Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis.

Authors:  Arnaud Machelart; Giuseppina Salzano; Xue Li; Aurore Demars; Anne-Sophie Debrie; Mario Menendez-Miranda; Elisabetta Pancani; Samuel Jouny; Eik Hoffmann; Nathalie Deboosere; Imène Belhaouane; Carine Rouanet; Sophie Simar; Smaïl Talahari; Valerie Giannini; Baptiste Villemagne; Marion Flipo; Roland Brosch; Fabrice Nesslany; Benoit Deprez; Eric Muraille; Camille Locht; Alain R Baulard; Nicolas Willand; Laleh Majlessi; Ruxandra Gref; Priscille Brodin
Journal:  ACS Nano       Date:  2019-03-08       Impact factor: 15.881

Review 6.  A Brief Overview of the Antitumoral Actions of Leelamine.

Authors:  Myriam Merarchi; Young Yun Jung; Lu Fan; Gautam Sethi; Kwang Seok Ahn
Journal:  Biomedicines       Date:  2019-07-19

7.  Targeting Protein Translation in Melanoma by Inhibiting EEF-2 Kinase Regulates Cholesterol Metabolism though SREBP2 to Inhibit Tumour Development.

Authors:  Saketh S Dinavahi; Yu-Chi Chen; Raghavendra Gowda; Pavan Kumar Dhanyamraju; Kishore Punnath; Dhimant Desai; Arthur Berg; Scot R Kimball; Shantu Amin; Jin-Ming Yang; Gavin P Robertson
Journal:  Int J Mol Sci       Date:  2022-03-23       Impact factor: 5.923

8.  EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAFV600E Mutated Parent- and Vemurafenib-Resistant Melanoma.

Authors:  Yige Fu; Drishti Rathod; Ehab M Abo-Ali; Vikas V Dukhande; Ketan Patel
Journal:  Pharmaceutics       Date:  2019-10-01       Impact factor: 6.321

Review 9.  Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives.

Authors:  Laurence Pellerin; Lorry Carrié; Carine Dufau; Laurence Nieto; Bruno Ségui; Thierry Levade; Joëlle Riond; Nathalie Andrieu-Abadie
Journal:  Cancers (Basel)       Date:  2020-10-27       Impact factor: 6.639

10.  Leelamine Modulates STAT5 Pathway Causing Both Autophagy and Apoptosis in Chronic Myelogenous Leukemia Cells.

Authors:  Young Yun Jung; Jae-Young Um; Arunachalam Chinnathambi; Chandramohan Govindasamy; Gautam Sethi; Kwang Seok Ahn
Journal:  Biology (Basel)       Date:  2022-02-25
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.